Skip to main content

Raise Your Profile

Whether you are looking to attract a new business client, investment and partnering deal flow or talent, among other goals, One Nucleus offers a wide range of opportunities to raise your profile to our members and to the Greater Cambridge cluster in particular.
Raise Your Profile
  • Discounts for Members

    Discounts for Members

    Members can take advantage of discounts on a wide range of products and services to maximise their return on the member subscription, often recovering multiples of the fees paid. Receive discounted rates on laboratory supplies, services, key industry events and more.
    Learn more
  • Connect with Our Network

    Connect with Our Network

    A key advantage to any company joining One Nucleus is the ability to connect to potential partners, investors, service providers, clients and their peers for knowledge-sharing. We do this through our varied range of informative networking events, which tend to be situated throughout Cambridge and London.
    Learn more
  • Build the Best Teams

    Build the Best Teams

    One Nucleus recognises that a company’s employees are its most valuable asset and the competition for talented and skilled employees has never been fiercer in the region’s life science sector. One Nucleus offers a range of services and engagement opportunities in this critical area to help support our members and maintain the reputation of the sector.
    Learn more

Events

Connecting and meeting with business partners, fellow innovators and key advisers is a vital part of everyone's endeavours since it enables knowledge exchange and onward contact for mutual and collective success. Complementing the wider One Nucleus support activities our portfolio of events is designed to meet the needs of our network in terms of content, format, timing, peer-to-peer engagements and modes of delivery.
  • Events
  • Events
  • Events
  • Events

Membership Overview

With Gold and Silver membership options, our 400 company members and their staff can benefit from a wide variety of savings, profiling opportunities, and more.
  • Membership

About One Nucleus

One Nucleus is a not-for-profit Life Sciences & Healthcare membership organisation headquartered in Cambridge. We support institutions, companies and individuals in the Life Sciences sector providing local, UK-wide and international connectivity. 
  • About

UK health: Focus on prevention can deliver £8 for each £1 invested

  • UK has the potential to unlock £8 in socio-economic returns for every £1 spent on preventive healthcare, according to new Deloitte analysis;
  • Increasing prevention spend from current 6% to 10% could lead to £42 billion of savings to the UK healthcare system in 10 years;
  • A 7% reduction in preventable deaths could save over 5,400 lives annually, with a societal value of £6 billion.

The UK has the potential to unlock £8[1] in socio-economic returns for every £1 spent on preventive healthcare, according to a new health report by Deloitte.

BIO-Europe Spring® 2026

Building and nurturing relationships is an essential part of successful business partnerships. BIO-Europe Spring brings together over 3,700 leading executives from around the world, hosting more than 20,000 partnering meetings between biotech companies, startups and academia with pharma companies and forward-thinking investors. 

Through partnership with One Nucleus partners, EBD Group, One Nucleus looks forward to supporting our members again this year at BIO-Europe Spring 2025.

Beacon’s Patient Group Mentoring Programme 26 – 27

Become a mentor on Beacon’s Patient Group Mentoring Programme and make a real difference to the rare disease community!

Mentees need support across a wide range of areas, from charity management and fundraising to communications, life sciences and more.

You don’t need a background in rare diseases to have something valuable to offer.

As a mentor, you will:

• Be paired with a rare disease patient group leader for a 12-month partnership

• Grow your leadership skills and aid your professional development

Enedra Therapeutics appoints Dr Adrian Ibrahim as Chief Executive Officer ahead of upcoming seed round

Enedra Therapeutics (Enedra), a pioneering biotechnology company focused on developing novel treatments for genetically heterogeneous cancers, today announced the appointment of Adrian Ibrahim, PhD, MBA, as its new Chief Executive Officer. Dr Ibrahim will also join the Company’s Board of Directors. His appointment comes as Enedra prepares to initiate its seed phase fundraising round.

DLRC Group Becomes a Certified B Corporation

[Letchworth Garden City, December 2025] – DLRC Group has today announced its certification as a B Corporation (or B Corp), joining a growing movement of companies that are reinventing business for the benefit of all people and our shared planet. Verified by B Lab, the not-for-profit behind the B Corp movement, the achievement demonstrates that DLRC Group meets high standards of social and environmental performance, transparency, and accountability alongside a commitment to goals beyond shareholder value.

Postdoctoral Research Scientist (Signalling)

We are seeking an enthusiastic and talented Postdoctoral Research Scientist to join the David group at the Babraham Institute in Cambridge.  Our overarching goal is to discover mechanisms that promote healthy ageing and alleviate age-related diseases such as Alzheimer’s disease. Our group has uncovered mechanisms that prevent age-related protein aggregation, a major contributor to functional decline. Notably, we discovered a proteostasis network that safeguards proteins from aggregation in the extracellular space in C.

Graduate Lab Technician

Role
As a Lab Tech/Protein Scientist you will be a critical part of our technical bioprocessing team, helping to produce alternative milk proteins. You’ll support both upstream (cloning, strain selection) fermentation and downstream (protein extraction and purification) in a fast-paced, innovation-driven lab environment.

Target Discovery Scientist (Research Biologist)

OutSee is a techbio startup that is defining the state of the art in genomic drug target discovery. Where current methods search for correlation between genetics and disease, our AI platform Nomaly searches for the causal biological mechanisms driving the disease.

So far, the techbio industry has its tunnel vision focused on the creation of binders. By applying our technology to target identification, we are transforming a fundamental but overlooked pillar of drug development.

Subscribe to